Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

MiRNA molecule miR-206 for regulating and controlling uterine muscle contraction and application of miRNA molecule miR-206

A mir-206, nucleic acid molecule technology, which can be used in the determination/inspection of medical preparations containing active ingredients, organic active ingredients, microorganisms, etc.

Pending Publication Date: 2022-07-15
GUANGZHOU WOMEN AND CHILDRENS MEDICAL CENTER
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the drugs for the clinical treatment of preterm labor are mainly chemical tocolytics, such as ritodrine hydrochloride, nifedipine, and atosiban, etc., which have their own contraindications and most of them are only used to prolong the gestational week by 48 hours to complete the promotion. The fetal lungs are mature, and the above drugs cannot achieve the effect of premature birth prevention and treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • MiRNA molecule miR-206 for regulating and controlling uterine muscle contraction and application of miRNA molecule miR-206
  • MiRNA molecule miR-206 for regulating and controlling uterine muscle contraction and application of miRNA molecule miR-206
  • MiRNA molecule miR-206 for regulating and controlling uterine muscle contraction and application of miRNA molecule miR-206

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0099] Example 1 Expression of miRNA-206 in laboring uterine muscle

[0100] 1. Collect samples

[0101] The inventor collected human uterine muscle tissue from full-term pregnancies and full-term pregnant women who underwent cesarean section at Guangzhou Women and Children's Medical Center. , the above samples are samples that exclude pregnancy complications such as gestational diabetes and eclampsia. Among them, the human uterine muscle tissue of full-term pregnancies (10 cases) was used as the control group, and the human uterine muscle tissue of full-term pregnant women (10 cases) was used as the control group. As the observation group, there was no significant difference in the BMI value and age of the pregnant women between the control group and the observation group. The informed consent of each pregnant woman has been obtained in advance, and all samples obtained have reached the consent of the organizational ethics committee.

[0102] 2. Tissue RNA Extraction and Se...

Embodiment 2

[0108] Example 2 Effects of mimics of miR-206 on GJA1 expression in uterine smooth muscle cells

[0109] 1. Primary culture of uterine smooth muscle cells

[0110] Human uterine smooth muscle tissue derived from caesarean section was collected, washed with Hanks solution to remove blood stains on the surface, and used surgical forceps to remove adhering connective tissue and other non-cultured tissues; after washing again, the tissue was cut into several small pieces with a scalpel , transfer into a penicillin vial or a small beaker, add PBS, and cut the tissue repeatedly with elbow ophthalmic scissors until the tissue becomes a paste, about 1mm 3 size. After standing for a while, the supernatant liquid was removed with a pipette, and an appropriate buffer was added to wash it again; use trypsin (the volume ratio of trypsin to tissue block is 1:0.25) to digest and separate the fine tissue block into cell clusters or dispersed cells. For single cells, to facilitate further cu...

Embodiment 3

[0117] Example 3 Therapeutic effects of miRNA-206 mimics in preterm animal models

[0118] In order to obtain the overexpression of miR-206, we used agomir of miR-206. agomir is a double-stranded small RNA that has undergone special chemical modification. It modulates the biological function of the corresponding target gene by mimicking endogenous miR-206. The base is modified with Ome (methoxyl group), and the antisense strand is modified with Chol (cholesterol), which can exist stably in mice and be easily taken up by cells. The corresponding agomir NC is used as a negative control. The sequence of agomiR-206 is: positive chain 5'-UGGAAUGUAAGGAAGUGUGUGG-3' (SEQ ID No. 8), reverse chain 5'-chol-CCACACACUUCCUUACAUUCCA-3' (SEQ ID No. 9).

[0119] CD1 mice (6-8 weeks old) were used to construct a premature birth model with mifepristone RU486. On the 15th day of pregnancy, the mice were injected subcutaneously with RU486 (200 μg / kg / d, prepared with sesame oil as 100 μL), and the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of biological medicines, discloses a miRNA molecule miR-206 for regulating and controlling uterine muscle contraction and application of the miRNA molecule miR-206, and particularly discloses application of miR-206, a precursor of miR-206 and / or a miR-206 simulant to preparation of a medicine for preventing and / or treating premature delivery. The invention discloses miR-206 as a treatment target of premature birth for the first time, the miR-206 is not reported to be related to premature birth before, and the contraction capacity of uterine smooth muscle cells can be remarkably inhibited through overexpression of miR-206, so that the effects of preventing and treating premature birth are achieved, and the morbidity of premature birth and the number of premature infants are reduced.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to a miRNA molecule miR-206 for regulating uterine muscle contraction and its application. Background technique [0002] Preterm birth, defined as delivery at 28 weeks and less than 37 weeks of gestation, is the leading cause of poor perinatal outcomes. Every year, more than 1 million newborns worldwide die due to premature birth and related complications. The preterm birth rate in China is about 5% to 15%, with more than 1.17 million premature babies per year. Neonatal death and severe injury related to preterm birth are serious medical and social problems. The core links of spontaneous preterm birth include premature cervical ripening, decidual activation and uterine contraction caused by various factors. At present, the drugs for the clinical treatment of preterm labor are mainly chemical tocolytics, such as ritodrine hydrochloride, nifedipine and atosiban, etc....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7105A61P15/06C12Q1/6883
CPCA61K31/7105A61P15/06C12Q1/6883C12Q2600/158C12Q2600/178
Inventor 冀开元刘慧姝邓雯锋陈利娜
Owner GUANGZHOU WOMEN AND CHILDRENS MEDICAL CENTER
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products